Passer au contenu principal

Lambert Busque

Busque, Lambert

Full professor

Affiliation

Université de Montréal

Research Axes

Immunology-oncology

Contact information

Phone: 514-252-3400, poste4674

lbusque.hmr@ssss.gouv.qc.ca

Team

  • Sammy Ayachi
  • Vincent Bourgoin
  • Manuel Buscarlet

Dr. Lambert Busque is a hematologist and the director of the Clinical Laboratory for Molecular Diagnosis and the Hematopoiesis and Aging Research Unit. He is also a full professor in the Faculty of Medicine at Université de Montréal.

Research Unit

Hematopoiesis and Aging

Research interests

  • Characterization of the molecular causes of the development of clonal hematopoiesis associated with aging.
  • Precision medicine in myeloid cancers [myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and chromic myeloid leukemia (CML)]
  • Clinical research in myeloid cancer (MDS, NMP and CML)
  • Busque L, Patel JP, Figueroa M, Vasanthakumar A, Provost S, Hamilou Z, Mollica L, Li J, Viale A, Heguy A, Hassim M9, Socci N, Gonen M, Mason CE, Melnick A, Godley LA, Brennan C, Abdel-Wahab O, Levine RL. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012 Nov 1;44(11):1179-81. PMID : 23001125.
  • Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014 May 29;123(22):e123-33. PubMed PMID: 24740812;.
  • Busque L, Porwit A, Day R, Olney HJ, Leber B, Éthier V, Sirhan S, Foltz L, Prchal J, Kamel-Reid S, Karsan A, Gupta V. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian MPN Group. Am J Clin Pathol. 2016 October;146(4):408-22. PMID: 27686169
  • Buscarlet M, Tessier A, Provost S, Mollica L, Busque L*. Human blood cell levels of 5-hydroxymethylcytosine (5hmC) decline with age, partly related to acquired mutations in TET2. Exp Hematol. 2016 November;44(11):1072-1084. PMID: 27475703
  • Buscarlet M, Provost S, Feroz Zada Y, Barhdadi A, Bourgoin V, Mollica L, Szuber N, Dubé MP, Busque L*. DNMT3A and TET2 dominate age-associated clonal hematopoiesis, have benign hematological phenotypes but different genetic predisposition. Blood (2017) 130 (6), 753-762.
  • Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and Evolution to Hematopoietic Malignancies. Cell Stem Cell 2018, 22: 157-170
  • Buscarlet M, Provost S, Feroz Zada Y, Vincent Bourgoin, Mollica L, Dubé MP, and Lambert Busque. Lineage restriction analyses in subjects with CHIP indicates a strong myeloid proliferation bias for TET2 and a multipotent stem cell origin for DNMT3A. Blood. 2018 Jul 19;132(3):277-280. PMID:29764839
  • Busque L, Buscarlet M, Mollica L, Levine RL. Stem Cells. Concise Review: Age-Related Clonal Hematopoiesis: Stem Cells Tempting the Devil. 2018 Sep;36(9):1287-1294. PMID:29883022

Education

  • Doctor of Medicine (hematology and molecular biology)

    Harvard University